Dementia of the Alzheimer’s type uncomplicated affects millions of people worldwide, and while there is no cure, modern medicine offers various approaches to manage symptoms and potentially slow the disease’s progression. Treatment strategies range from established medications to experimental therapies currently being tested in research studies.

Guiding Treatment Decisions: What Matters Most

When someone receives a diagnosis of Alzheimer’s disease, the primary goals of treatment focus on maintaining quality of life, managing symptoms, and preserving independence for as long as possible. Treatment approaches differ depending on how far the disease has advanced and the individual characteristics of each patient, including their age, overall health, and how severe their symptoms are.^[1]

Medical societies and healthcare organizations have developed standard treatment guidelines that doctors follow when caring for people with Alzheimer’s. These guidelines are based on years of research and clinical experience. At the same time, scientists continue to explore new therapies through clinical trials, testing innovative medications and approaches that might offer better results than what is currently available.^[10]

The stage of Alzheimer’s disease plays a significant role in determining which treatments are most appropriate. Early-stage disease, where symptoms are mild and people can still perform most daily activities, may be treated differently than moderate or severe disease, where individuals need more help with basic tasks. Understanding where someone falls on this spectrum helps doctors tailor treatment plans to individual needs.^[2]

Every person with Alzheimer’s experiences the disease differently. Some may have more memory problems, while others struggle more with behavior changes or difficulty with language. This variability means that treatment must be personalized, taking into account not just the disease itself but also the person’s living situation, family support, and personal preferences.^[7]

Standard Treatment Approaches

The foundation of Alzheimer’s treatment relies on medications that have been approved by regulatory authorities like the U.S. Food and Drug Administration. These treatments fall into several categories, each working differently to address the symptoms of the disease.^[12]

Cholinesterase Inhibitors

The most commonly prescribed medications for mild to moderate Alzheimer’s disease are called cholinesterase inhibitors. These drugs work by preventing the breakdown of acetylcholine, a chemical in the brain that is important for memory and thinking. As Alzheimer’s progresses, the brain produces less acetylcholine, and these medications help preserve what remains.^[14]

Three cholinesterase inhibitors are widely used: donepezil, rivastigmine, and galantamine. Donepezil can be prescribed for all stages of Alzheimer’s, from mild to severe, while rivastigmine and galantamine are typically used for mild to moderate disease. These medications may help reduce or control some cognitive and behavioral symptoms, though they do not stop the disease from progressing.^[12]

The effects of these medications are modest. Some people experience improvements in memory, thinking, and daily functioning, while others notice that symptoms progress more slowly than they might have without treatment. However, the medications work in similar ways, so switching from one to another may not produce dramatically different results, although some individuals respond better to one medication than others.^[14]

Common side effects of cholinesterase inhibitors include nausea, vomiting, diarrhea, and loss of appetite. These digestive problems can be uncomfortable but often improve after the body adjusts to the medication. More serious side effects can include dizziness, confusion, slow heart rate, and irregular heart rhythms. Because of these potential issues, doctors monitor patients carefully, especially when starting treatment or increasing doses.^[16]

Treatment with cholinesterase inhibitors typically continues as long as the person appears to benefit. Over time, as Alzheimer’s advances, these medications may become less effective because the brain produces even less acetylcholine. Doctors may eventually recommend stopping the medication if it no longer seems helpful.^[15]

Memantine for Moderate to Severe Disease

For people with moderate to severe Alzheimer’s disease, another type of medication called memantine is available. Memantine works differently from cholinesterase inhibitors. It blocks the action of glutamate, a brain chemical that, in excess amounts, can damage nerve cells. By regulating glutamate activity, memantine may help protect brain cells from further damage.^[14]

Memantine can modestly improve measures of cognition, behavior, and the ability to perform daily activities in people with moderate to severe Alzheimer’s. It can be used alone or in combination with a cholinesterase inhibitor, and some evidence suggests that combining these two types of medications may provide greater benefits than using either one alone.^[12]

This medication is generally well tolerated, with fewer side effects than cholinesterase inhibitors. Some people may experience dizziness, headache, confusion, or constipation, but serious side effects are relatively rare. Despite its benefits, there is ongoing debate among medical professionals about whether the improvements memantine produces are meaningful enough to significantly improve quality of life.^[14]

Managing Behavioral and Psychiatric Symptoms

As Alzheimer’s disease progresses, many people develop behavioral and psychiatric symptoms such as agitation, aggression, hallucinations, delusions, depression, or anxiety. These symptoms can be distressing for both the person with dementia and their caregivers. While non-drug approaches like creating a calm environment and maintaining routines are usually tried first, medications are sometimes needed.^[10]

Atypical antipsychotic medications are sometimes prescribed to manage severe behavioral symptoms, particularly aggression or psychosis. However, these medications come with significant risks. Studies have shown that atypical antipsychotics are associated with increased mortality rates in older people with dementia. Because of these serious safety concerns, these medications should only be used when symptoms are severe and other approaches have failed, and they should be prescribed at the lowest effective dose for the shortest possible time.^[16]

For depression and anxiety, antidepressants may be prescribed. Sleep problems can sometimes be managed with medications, but non-drug approaches like maintaining a regular sleep schedule and reducing daytime napping are usually tried first.^[10]

Disease-Modifying Treatments

A newer category of medications aims to address the underlying biology of Alzheimer’s disease rather than just treating symptoms. These are called disease-modifying treatments, and they work by targeting the abnormal proteins that accumulate in the brain of people with Alzheimer’s.^[17]

Two medications in this category have received FDA approval: lecanemab and donanemab. These are immunotherapy drugs that target beta-amyloid, a protein that forms plaques in the brain. By removing these plaques, the medications may slow the progression of cognitive decline in people with early Alzheimer’s disease.^[17]

Lecanemab received traditional FDA approval in 2024 for treating early Alzheimer’s disease. In clinical trials, it slowed the rate of cognitive and functional decline in study participants over 18 months compared to those who received a placebo. Similarly, donanemab, marketed as Kisunla, also received FDA approval in 2024 after clinical trials showed it could slow progression by approximately 35% in people with early signs of Alzheimer’s disease.^[12]

Before prescribing these medications, doctors typically order specialized tests to confirm that amyloid plaques are present in the brain. This may involve a PET scan or analysis of cerebrospinal fluid. These drugs are given as intravenous infusions, requiring regular visits to a healthcare facility. They also come with potential side effects, including brain swelling and small brain bleeds, which require careful monitoring with MRI scans during treatment.^[14]

Insurance coverage for these newer treatments can be limited. Medicare Part B covers part of the cost for patients who meet specific medical criteria. The high cost and need for frequent monitoring make these treatments less accessible to many people who might benefit from them.^[14]

Treatment in Clinical Trials

Beyond the medications already approved for use, numerous experimental therapies are being tested in clinical trials around the world. These research studies are crucial for discovering whether new treatments are safe and effective before they can be made widely available to patients.^[10]

How Clinical Trials Work

Clinical trials typically progress through three main phases. Phase I trials focus primarily on safety, testing a new drug in a small number of people to determine what dose is safe and what side effects might occur. Phase II trials involve more participants and begin to evaluate whether the treatment actually works—that is, whether it improves symptoms or slows disease progression. Phase III trials are large studies that compare the new treatment to the current standard of care or a placebo to determine if the new approach is better.^[15]

Participation in clinical trials is voluntary, and people can withdraw at any time. Trials have specific eligibility requirements based on factors like disease stage, age, other health conditions, and previous treatments. Some trials are conducted at multiple locations, including in the United States, Europe, and other regions, making them more accessible to potential participants.^[10]

Targeting Tau Protein

While beta-amyloid plaques are one hallmark of Alzheimer’s disease, another characteristic feature is the accumulation of tau tangles inside brain cells. Tau is a protein that normally helps maintain cell structure, but in Alzheimer’s, it becomes abnormal and forms twisted tangles that damage and kill neurons.^[15]

Researchers are testing various approaches to target tau protein. Some experimental drugs aim to prevent tau from forming tangles in the first place. Others try to remove existing tangles from the brain or stop abnormal tau from spreading from one brain cell to another. These therapies are in different stages of clinical testing, with some showing promising early results in slowing cognitive decline.^[15]

Anti-Inflammatory Approaches

Inflammation, or swelling and immune system activation in the brain, appears to play a role in Alzheimer’s disease progression. This has led researchers to investigate whether reducing brain inflammation might slow the disease. Various anti-inflammatory therapies are being explored in clinical trials, though results so far have been mixed. Some approaches focus on specific immune cells in the brain called microglia, which can become overactive and contribute to neuron damage.^[15]

Neuroprotective Strategies

Neuroprotective treatments aim to help brain cells survive and function better despite the disease process. These approaches include medications that support cellular energy production, protect against oxidative stress (a type of cellular damage), or promote the growth and survival of neurons. Many different molecules are being tested with this goal in mind, though none have yet proven definitively effective in large clinical trials.^[15]

Lifestyle and Metabolic Interventions

Some clinical trials are investigating whether factors like diet, exercise, and medications that affect metabolism might influence Alzheimer’s progression. For example, insulin resistance and diabetes appear to increase Alzheimer’s risk, leading to studies of diabetes medications in people with dementia. However, studies of insulin-sensitizing drugs have not shown clear benefits for treating Alzheimer’s disease so far.^[16]

Gene Therapy and Emerging Technologies

Gene therapy is an experimental approach that involves delivering genetic material into cells to produce beneficial proteins or correct genetic problems. While gene therapy is being explored for Alzheimer’s, it is still in very early stages of research. Other cutting-edge approaches being investigated include stem cell therapies, which aim to replace damaged brain cells or support the survival of existing cells.^[15]

Trial Locations and Eligibility

Clinical trials for Alzheimer’s disease are conducted at research centers throughout the United States, Europe, and other parts of the world. Major medical centers and universities often have dedicated research programs that recruit participants. The Alzheimer’s Association maintains a database called TrialMatch that helps people find clinical trials they might be eligible for based on their diagnosis, location, and other factors.^[10]

Eligibility for trials varies widely. Some studies focus on people with very early disease or even those without symptoms but at high risk. Others recruit participants with moderate or advanced disease. Trials may require specific biomarker results, such as evidence of amyloid in the brain, or may exclude people taking certain medications or with particular health conditions.^[15]

Most common treatment methods

• Cholinesterase Inhibitors
  • Donepezil, rivastigmine, and galantamine prevent the breakdown of acetylcholine in the brain
  • Used for mild to moderate Alzheimer’s disease, with donepezil also approved for severe disease
  • May help reduce memory loss and confusion, though effects are modest
  • Common side effects include nausea, vomiting, diarrhea, and digestive problems
• NMDA Receptor Antagonists
  • Memantine blocks excess glutamate activity to protect brain cells
  • Prescribed for moderate to severe Alzheimer’s disease
  • Can be used alone or combined with cholinesterase inhibitors
  • Generally well tolerated with fewer side effects than other Alzheimer’s medications
• Anti-Amyloid Immunotherapies
  • Lecanemab and donanemab target beta-amyloid plaques in the brain
  • Approved for early-stage Alzheimer’s disease with confirmed amyloid presence
  • Given as intravenous infusions at specialized healthcare facilities
  • Slow the rate of cognitive decline over time rather than stopping disease progression
  • Require regular monitoring for potential brain swelling and bleeding
• Behavioral Symptom Management
  • Atypical antipsychotics for severe agitation, aggression, or psychosis
  • Used with caution due to increased mortality risk in older people with dementia
  • Antidepressants for depression and anxiety symptoms
  • Sleep medications or sleep management strategies for sleep disturbances
• Non-Drug Approaches
  • Maintaining daily routines and structured schedules to reduce confusion
  • Creating safe, comfortable home environments adapted for dementia
  • Physical activity and exercise programs to support overall health
  • Social engagement and mentally stimulating activities
  • Caregiver education and support programs

Supporting Daily Life with Alzheimer’s

Treatment for Alzheimer’s disease goes beyond medication. Creating supportive environments and implementing practical strategies can significantly improve quality of life for people with dementia and their caregivers.^[19]

Establishing daily routines helps reduce confusion and anxiety. When people with Alzheimer’s know what to expect each day, they often feel more secure and less agitated. This might include eating meals at the same times, following a consistent bedtime routine, and scheduling activities when the person is typically most alert.^[20]

Adapting the home environment can enhance safety and independence. This includes removing clutter and tripping hazards, installing good lighting throughout the house, using contrasting colors to help people distinguish objects from their surroundings, and placing labels or signs on doors and cabinets. Simple modifications like these can help people with dementia navigate their homes more easily.^[27]

Communication strategies become increasingly important as the disease progresses. Speaking slowly, using simple sentences, maintaining eye contact, and giving the person time to respond can all improve interactions. Patience and understanding are essential, as frustration can worsen behavioral symptoms.^[23]

Physical activity, even simple walking or gentle exercises, can help maintain mobility, improve mood, and potentially slow some aspects of cognitive decline. Social engagement and activities that the person enjoys should be continued as long as possible, adapted as needed to match their current abilities.^[19]

Caregivers need support too. Caring for someone with Alzheimer’s is physically and emotionally demanding. Caregiver burnout is common, affecting approximately 60% of family caregivers. Taking breaks, asking for help, joining support groups, and maintaining one’s own health are not luxuries but necessities for sustainable caregiving.^[25]